Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
Clinicopathologic Conference, Cerebrovascular Accident Probably Related to SARS-CoV2 Infection
NEJM 383:764-773, Case 26-2020, 2020
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Paraneoplastic and Autoimmune Encephalitis
UptoDate July, Dalmau, J.,et al, 2017
Antibiotic-Associated Encephalopathy
Neurol 86:963-971, Bhattacharyya, S.,et al, 2016
Synthetic Cannabinoid-Related Illnesses and Deaths
NEJM 373:103-107, Trecki, J.,et al, 2015
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Marijuana
Adams & Victors Principles of Neurology Ch 43, pg 1214, Ropper, A.H.,et al, 2014
Inherited Metabolic Diseases of the Nervous System, Hepatolenticular Degeneration (Wilson Disease)
Adams & Victors Principles of Neurology, Chp 37, pg 982, Ropper, A.H.,et al, 2014
Frequency and Characteristics of Isolated Psychiatric Episodes in Anti-N-Methyl-D-Aspartate Receptor Encephalitis
JAMA Neurol 70:1133-1139, Kayser, M.S.,et al, 2013
Clinicopathologic Conference, Methcathinone (Bath Salts) Intoxication
NEJM 369:2536-2545, Case 40-2013, 2013
Clinicopathologic Conference,Disseminated Infection with Mycobacterium Tuberculosis of Liver,Peripancreatic Lymphnodes,Sputum,Blood & Urine with Acute Psychosis and HIV.
NEJM 366:648-657, Case 5-2012, 2012
Relapse Risk after Discontinuation of Risperidone in Alzheimers Disease
NEJM 367:1497-1507, Devanand, D.P.,et al, 2012
The Frequency of Autoimmune N-Methyl-D-Aspartate Receptor Encephalitis Surpasses That of Individual Viral Etiologies in Young Individuals Enrolled in the California Encephalitis Project
Clin Inf Dis 54:899-904, Gable, M.S.,et al, 2012
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Autoimmune encephalitis
BMJ 342:d1918, Irani, S.R.,et all, 2011
Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
Arch Neurol 68:899-904, Weintraub, D.,et al, 2011
"Bath Salts" Intoxication
NEJM 365:967-968, Ross, E.A.,et al, 2011
Treatment of Severe Neurological Deficits with IgG Depletion through Immunoadsorption in Patients with Escherichia coli O104:H4-Associated Haemolytic Uraemic Syndrome: A Prospective Trial
Lancet 378:1166-1173,1120, Greinacher, A.,et al, 2011
Anti-N-Methyl-d-Aspartate Receptor Encephalitis: Characteristic Behavioral and Movement Disorder
Arch Neurol 67:250-251, Ferioli,S.,et al, 2010
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
Psychotropic Effects of Antiepileptic Drugs
Neurol 67:1916-1925, Ettinger,A.B., 2006
Psychosis Related to Ropinirole
Am J Psychiatry 163:546-547, Perea,E.,et al, 2006
Mitochondrial DNA Polymerase-y and Human Disease
Hum Mol Genet 15:R244-R252, Hudson, G.,et al, 2006
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
A 48-Year-Old Man With Temporal Lobe Epilepsy and Psychiatric Illness
JAMA 290:381-392, Devinsky,O., 2003
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Clinicopath Conf, Strychnine Poisoning, Case 12-2001
NEJM 344:1232-1239, , 2001
The Neurologic Complications of Scleromyxedema
Medicine 80:313-319, Berger,J.R.,et al, 2001
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000
Niemann-Pick Disease Type C: Two Cases and an Update
Movement Disorders 15:1199-1203, Uc,E.Y.,et al, 2000
Central Anticholinergic Syndrome on Therapeutic Doses of Cyproheptadine
Pediatrics 103:158-160, Watemberg,N.M.,et al, 1999
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Transderm-induced Psychosis in Parkinson's Disease
Neurol 53:433-434, Minagar,A.,et al, 1999
Diagnosing Dementia with Lewy Bodies
Lancet 354:1227-1228, McKeith,I.G.,et al, 1999
Psychiatric Adverse Events During Vigabatrin Therapy
Neurol 53:1503-1511, Levinson,D.F.&Devinsky,O., 1999
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
Susac Syndrome
Medicine 77:3-11, Papo,T.,et al, 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Complications of Sedation with Midazolam in the Intensive Care Unit and a Comparison with Other Sedative Regimens
Crit Care Med 26:947-956, Shafer,A., 1998
Subcotical Arteriosclerotic Encephalopathy (Binswangers Disease)
, Ghika,J. &Bogousslavsky, J., 1998
Clinical Features and Pharmacologic Treatment of Behavioral Symptoms of Alzheimer's Disease
Neurol 48 (Suppl 6) :S17-S24997., Borson,S.&Raskind,M.A., 1997
Olanzapine:A Novel Atypical Neuroleptic Agent
Lancet 349:1264-1265, Reus,V.I., 1997